证券代码：300667 证券简称：必创科技 公告编号：2024-025 北京必创科技股份有限公司 2023 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无增加、变更、否决提案的情况； 2、本次股东大会不涉及变更前次股东大会决议。 一、 会议召开情况 1、召开方式：本次股东大会采取现场表决与网络投票相结合的方式召开。 2、现场会议召开的时间：2024 年 5 月 13 日下午 14:00。 3、网络投票时间： 通过深圳证券交易所互联网系统进行投票的具体时间为 2024 年 5 月 13 日上 午 9:15 至下午 15:00 的任意时间；通过深圳证券交易所交易系统进行网络投票 的时间为：2024 年 5 月 13 日上午 9:15-9:25、9:30-11:30、下午 13:00-15:00。 4、现场会议召开地点：北京市海淀区上地七街 1 号汇众 2 号楼六层公司第 一会议室。 5、会议召集人：公司董事会 6、会议主持人：董事长代啸宁先生 本次会议的召集、召开符合《中华人民共和国公司法》（以下简称《公司法 ...

北京市金杜律师事务所 关于北京必创科技股份有限公司 2023 年年度股东大会的 法律意见书 致：北京必创科技股份有限公司 北京市金杜律师事务所（以下简称本所）接受北京必创科技股份有限公司（以 下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证券法》）、《中 华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理委员会《上市公 司股东大会规则（2022 年修订）》（以下简称《股东大会规则》）及《深圳证券交 易所上市公司股东大会网络投票实施细则（2020 年修订）》等中华人民共和国境 内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特别行政区、 中国澳门特别行政区和中国台湾地区）现行有效的法律、行政法规、规章和规范 性文件和现行有效的《北京必创科技股份有限公司章程》（以下简称《公司章程》） 有关规定，指派律师出席了公司于 2024 年 5 月 13 日召开的 2023 年年度股东大 会（以下简称本次股东大会），并就本次股东大会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1. 经公司 2023 年第二次临时股东大会审议通过的《公司章程》 ...

Financial Performance - The company's revenue for Q1 2024 was ¥157,094,481.31, a decrease of 24.71% compared to ¥208,651,064.63 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥3,540,436.54, representing a decline of 124.68% from a profit of ¥14,343,586.64 in Q1 2023[5] - The net cash flow from operating activities was -¥23,078,679.29, a significant decrease of 678.02% compared to -¥2,966,351.88 in the previous year[5] - The company reported a basic and diluted earnings per share of -¥0.02, a decrease of 128.57% from ¥0.07 in Q1 2023[5] - The company's net profit margin for Q1 2024 was impacted by increased operating costs, leading to a net loss in investment income of ¥682,647.47 compared to a loss of ¥270,767.18 last year[21] - The net profit for Q1 2024 was -4,284,950.60 CNY, a significant decline compared to the net profit of 14,276,909.35 CNY in Q1 2023, representing a year-over-year decrease of approximately 130%[22] - Operating profit for Q1 2024 was -3,598,513.78 CNY, compared to an operating profit of 18,068,837.64 CNY in the same period last year, indicating a decline of around 120%[22] - Total comprehensive income for Q1 2024 was -4,171,806.34 CNY, down from 13,486,880.45 CNY in Q1 2023, reflecting a decrease of approximately 131%[23] Cash Flow and Assets - The company's cash and cash equivalents decreased to ¥341,883,198.93 from ¥400,831,739.15, a decline of 14.7%[18] - Total assets at the end of Q1 2024 were ¥1,578,630,944.54, down 1.79% from ¥1,607,451,299.21 at the end of the previous year[5] - The total current assets decreased to ¥863,482,802.62 from ¥908,541,988.00, a decrease of 5.0%[18] - Cash and cash equivalents at the end of Q1 2024 were 340,843,126.43 CNY, down from 383,092,841.31 CNY at the end of Q1 2023, a decrease of about 11%[25] Investment Activities - Long-term equity investments increased by 89.18% to ¥42,676,650.21, primarily due to increased external investments during the reporting period[9] - The company experienced a 900.41% decrease in net cash flow from investing activities, amounting to -¥22,176,437.67, compared to -¥2,216,738.40 in the previous year[9] - The company’s investment activities resulted in a net cash outflow of -22,176,437.67 CNY in Q1 2024, compared to -2,216,738.40 CNY in Q1 2023, indicating increased investment expenditures[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,157, with no preferred shareholders[10] - The top shareholder, Chen Fashu, holds 16,192,557.00 shares, accounting for 7.99% of the total shares[12] - The total number of shares held by the top 10 shareholders is 32,450,157.00, with a significant portion being locked under management restrictions[14] - The total number of shares held by the top 10 unrestricted shareholders is 28,170,246.00, indicating a stable ownership structure[12] - The management has confirmed that there are no changes in the shareholding structure among the top shareholders[12] Research and Development - Research and development expenses increased by 41.06% to ¥19,924,460.71 from ¥14,124,964.03 in Q1 2023, indicating a focus on innovation[9] - Research and development expenses increased to ¥19,924,460.71, up 41.4% from ¥14,124,964.03 in the previous year[21] Operational Performance - Total operating revenue for Q1 2024 was ¥157,094,481.31, a decrease of 24.7% compared to ¥208,651,064.63 in the same period last year[21] - Total operating costs for Q1 2024 were ¥163,425,759.17, down 16.1% from ¥194,841,746.39 year-over-year[21] - The company reported a decrease in sales revenue from 187,206,446.33 CNY in Q1 2023 to 185,258,567.39 CNY in Q1 2024, a decline of approximately 1%[24] Credit and Foreign Exchange - The company incurred credit impairment losses of 1,584,359.87 CNY in Q1 2024, compared to a reversal of 960,359.21 CNY in Q1 2023, indicating a significant deterioration in credit quality[22] - The company reported a foreign exchange loss of -99,608.18 CNY in Q1 2024, compared to a loss of -833,900.57 CNY in Q1 2023, showing an improvement in foreign exchange impacts[25] Miscellaneous - The company’s subsidiary, Jiangsu Shuangli Hepu Technology Co., Ltd., received a high-tech enterprise certificate, enhancing its market position[15] - The company has not reported any changes in the number of restricted shares for the current period[13] - The company has not engaged in any share lending or borrowing activities during this reporting period[13] - The company has not disclosed any new product developments or market expansion strategies in this report[15] - The company’s financial statements for Q1 2024 are prepared as of March 31, 2024, and are available for review[16]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》《深圳证券交易所创业板上市公司自律监管指南第 1 号——业务办理》 等有关规定的要求，北京必创科技股份有限公司（以下简称"公司"）对 2023 年度控股股东及其他关联方占用公司资金情况进行了核查；同时中瑞诚会计师事 务所（特殊普通合伙）（以下简称"中瑞诚"）对公司 2023 年度非经营性资金 占用及其他关联资金往来情况进行了审核，并出具了专项报告。具体内容公告如 下： 一、2023 年度控股股东及其他关联方占用资金情况说明 证券代码：300667 证券简称：必创科技 公告编号：2024-017 北京必创科技股份有限公司 关于控股股东及其他关联方占用资金情况的专项公告 2023 年度非经营性资金占用及其他关联资金往来情况汇总表 2023 年度，公司控股股东及其他关联方不存在违规占用公司资金的情况， 也不存在以前年度发生并累积至 2023 年 12 月 31 日的控股股东及其他关联方违 规占用公司资金的情况。具体情况详见附件《北京必创科技 ...

证券代码：300667 证券简称：必创科技 公告编号：2024-019 北京必创科技股份有限公司 关于举行 2023 年度业绩说明会并征集相关问题的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京必创科技股份有限公司（以下简称"公司"）2023 年年度报告全文及其 摘要于 2024 年 4 月 22 日在深圳证券交易所创业板指定信息披露网站巨潮资讯网 （www.cninfo.com.cn）披露。 为使广大投资者能够进一步了解公司的生产经营等情况，公司定于 2024 年 4 月 25 日下午 15:00-17:00 通过深圳证券交易所"互动易"平台"云访谈"栏 目举办 2023 年度网上业绩说明会，本次年度业绩说明会将采用网络远程的方式 举行，投资者可登陆深圳证券交易所"互动易"平台（http://irm.cninfo.com.cn）， 进入"云访谈"栏目参与本次说明会。 出席本次年度业绩说明会的人员有：董事长、总经理代啸宁先生，董事、财 务负责人、副总经理姜明杰先生，独立董事崔启龙先生，董事会秘书、副总经理 胡丹女士。 为充分尊重投资者、提升交流的针 ...

北京必创科技股份有限公司专项审核报告 北京必创科技股份有限公司 专项审核报告 中瑞诚审鉴字[2024]第 401845 号 中瑞诚会计师事务所（特殊普通合伙） 地址：北京市西城区金融大街 35 号 1 号楼 805# 电话：010-62267688 邮编：100033 传真：62267682 北京必创科技股份有限公司专项审核报告 目 录 专项审核报告 2023年度非经营性资金占用及其他关联资金 往来情况汇总表 会计师事务所营业执照、资格证书 北京必创科技股份有限公司专项审核报告 关于北京必创科技股份有限公司 2023 年度非经营性资金占用及其他关联资金往来情况汇总表 的专项审核报告 我们接受委托，在审计了北京必创科技股份有限公司（以下简称必创 科技公司）2023 年 12 月 31 日合并及母公司的资产负债表，2023 年度合 并及母公司的利润表、合并及母公司的现金流量表和合并及母公司的股东 权益变动表以及财务报表附注的基础上，对后附的必创科技公司《2023 年度非经营性资金占用及其他关联资金往来情况汇总表》（以下简称"汇 总表"）进行了专项审核。按照中国证券监督管理委员会印发的《上市公 司监管指引第 8 号 ...

北京必创科技股份有限公司 2023 年度董事会工作报告 北京必创科技股份有限公司（以下简称"公司"）董事会严格按照《中华人 民共和国公司法》《中华人民共和国证券法》《深圳证券交易所创业板股票上市 规则》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运 作》等法律法规、规范性文件及《公司章程》《董事会议事规则》的相关规定， 本着对全体股东负责的态度，恪尽职守、诚实守信、勤勉尽责地履行董事会职责， 贯彻落实公司股东大会各项决议，有效开展董事会各项工作，保障了公司良好的 运作和可持续发展。现将董事会2023年度工作情况汇报如下： 一、公司主要经营情况 | | 近红外二区便携式高光谱成像仪 | 科学研究、工业检测、智 | | --- | --- | --- | | | GaiaField-RT-NIR | 能制造 | | | 可见-近红外高光谱相机 Image-RT10 | 科学研究、工业检测、智 能制造 | | | 近红外二区高光谱相机 Image-RT17 | 科学研究、工业检测、智 能制造 | | | 高光谱数据分析软件 HyperScan Pro | 科学研究、工业检测、智 | | | | ...

Financial Performance - The company's operating revenue for 2023 reached ¥893,762,076.4, representing a 24.43% increase compared to ¥718,304,978.1 in 2022[23]. - Net profit attributable to shareholders was ¥36,288,097.38, a significant increase of 774.55% from ¥3,970,209.92 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was ¥24,175,352.10, up 464.74% from a loss of ¥6,807,318.42 in 2022[23]. - The basic and diluted earnings per share both increased to ¥0.17, a 750% rise from ¥0.02 in 2022[23]. - The total assets at the end of 2023 were ¥1,607,451,299, a decrease of 3.61% from ¥1,665,138,427 in 2022[23]. - The net assets attributable to shareholders increased by 4.09% to ¥1,276,536,506 from ¥1,226,257,913 in 2022[23]. - The net cash flow from operating activities for 2023 was ¥96,266,840.45, a decrease of 5.52% compared to ¥101,896,001.50 in 2022[23]. - The company achieved operating revenue of 893.76 million yuan, a year-on-year increase of 24.43%[98]. - Net profit attributable to shareholders increased by 774.55% to 36.29 million yuan, while net profit after deducting non-recurring gains and losses rose by 464.74% to 24.18 million yuan[98]. - The company reported a net cash flow from operating activities of ¥96,266,840.45, a decrease of 5.52% compared to the previous year[127]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 1.00 RMB per 10 shares to all shareholders, based on a total of 202,764,889 shares[3]. - The participation ratio for the 2023 first extraordinary general meeting was 37.49%[189]. - The participation ratio for the 2022 annual general meeting was 38.98%[189]. - The participation ratio for the 2023 second extraordinary general meeting was 30.98%[189]. - The participation ratio for the 2023 third extraordinary general meeting was 24.14%[189]. - The chairman and general manager, Dai Xiaoning, reduced his shareholding by 9,390,000 shares, bringing his total to 28,170,246 shares[190]. Research and Development - The company has a significant focus on research and development in areas such as Raman spectroscopy and fluorescence spectroscopy[16]. - Research and development investment totaled 85.83 million yuan, reflecting the company's commitment to enhancing product competitiveness and expanding new applications[98]. - The company holds a total of 69 invention patents, 104 utility model patents, 12 design patents, and 122 software copyrights, showcasing its strong innovation capabilities[89]. - The company is focusing on developing core technologies such as molecular spectroscopy, intelligent sensors, and precision displacement, enhancing its application innovation capabilities and accelerating the launch of differentiated products[99]. - The company is enhancing its operational management digitalization, focusing on cost control and risk prevention to improve operational efficiency[105]. - The company is committed to continuous product performance improvement and technical service capabilities to solidify its position as a leading enterprise in niche markets[99]. Market Strategy and Expansion - The company has established multiple wholly-owned subsidiaries to enhance its operational capabilities and market reach[15]. - The company is actively pursuing mergers and acquisitions to strengthen its market position and expand its product offerings[16]. - The company aims to leverage its technological strengths to capture core technologies and applications in the rapidly evolving digital economy[36]. - The company is positioned to benefit from the ongoing push for domestic substitution in the scientific instrument sector, which is expected to drive long-term growth[34]. - The company is expanding its market presence in the pharmaceutical and high-end food sectors with new wireless temperature recording products[124]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[194]. Product Development and Innovation - The company has developed a series of cold chain products, including temperature and humidity monitoring devices for pharmaceutical storage and transportation, ensuring full lifecycle cold chain safety and traceability[54]. - The company has launched an intelligent monitoring technology for equipment operation status, which has been continuously applied and iterated in various industrial scenarios, responding to the demand for digital and intelligent upgrades in manufacturing[48]. - The company has developed advanced sensing technologies, including optical and force-sensitive technologies, achieving high domestic and some international performance standards[89]. - The company is developing a high-end pharmaceutical spectral imaging and detection analysis instrument, aiming to achieve real-time analysis of spectral data, which is expected to significantly enhance pharmaceutical research and safety[121]. - The company is developing a new underwater sound speed measurement technology aimed at real-time acquisition of sound speed profile data, addressing urgent needs in underwater acoustic detection[124]. Corporate Governance and Social Responsibility - The company reported a strong commitment to corporate governance and social responsibility, as detailed in the annual report[5]. - The company has established a complete and independent R&D, procurement, production, and sales system, ensuring it can operate independently in the market[183]. - The company has a dedicated financial department with an independent financial accounting system, ensuring no interference from the controlling shareholder in financial decisions[185]. - The company has implemented a transparent performance evaluation and incentive mechanism for senior management, ensuring compliance with legal regulations[177]. - The company has maintained effective communication with stakeholders, balancing the interests of shareholders, employees, and society[180]. Risks and Challenges - The company faces growth risks due to external factors such as macroeconomic conditions and industry competition, which could significantly impact future performance[160]. - There is a risk of goodwill impairment if the acquired entity does not meet expected performance, which could adversely affect the company's financial results[162]. - The company is addressing market competition risks by investing in R&D, product quality, and market promotion to provide competitive solutions[164]. Customer and Market Engagement - The company emphasizes customer-driven product development, ensuring that core components and application systems meet diverse client requirements[57]. - The company has a robust customer base across various industries, which supports the development and optimization of new products[94]. - The company is focusing on brand building through participation in industry exhibitions and user seminars to enhance its reputation in the industrial automation sector[150]. - Customer satisfaction ratings improved to 90%, reflecting the effectiveness of recent service enhancements[200].

北京必创科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称"企业内部控制规范体系"），结合北京必创科技股份有限公司（以 下简称"公司"）的《内部控制管理制度》和《内部控制评价管理办法》，在公 司内部控制日常监督、专项监督基础上，我们对公司2023年12月31日（内部控制 评价报告基准日）的内部控制有效性进行了评价。 一、 重要声明 北京必创科技股份有限公司 2023年度内部控制自我评价报告 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性、完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性，故仅能为实现上述目标提供合理保证。此外， ...

证券代码：300667 证券简称：必创科技 公告编号：2024-012 北京必创科技股份有限公司 关于公司及全资子公司申请综合授信 额度及担保事项的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 （一）申请综合授信额度概况 北京必创科技股份有限公司（以下简称"公司"或"必创科技"）于 2024 年 4 月 19 日召开的第四届董事会第三次会议和第四届监事会第三次会议，审议通过了 《关于公司及全资子公司申请综合授信额度及担保事项的议案》，该议案尚需提交 公司股东大会审议。本事项不构成关联交易。现将有关情况公告如下： 一、申请综合授信额度概况及担保情况 单位：万元 | | | 担保方 | 被担保方 | 截至目 | 本次新 | 本次新增 | 担保额度占 | 是否 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 担保 | 被担 | 持股比 | 最近一期 | 前担保 | 增授信 | 非融资性 | 上市公司最 | 关联 | | 方 | 保方 | 例 | 资产负债 | 余额 | 担保额 | 担保额 ...